Frail older adults hospitalized with non–ST-elevation myocardial infarction (NSTEMI) did not experience improved outcomes with a routine invasive strategy compared with conservative medical management ...
I initiate Rezolute (RZLT) with a hold rating, reflecting a balanced risk/reward amid significant clinical and regulatory ...
VentureBeat research finds 72% of enterprises are running multiple "primary" AI platforms with no clear owner — creating ...
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, ...
Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
Chronic intranasal oxytocin alters neural connectivity in ASD but fails to significantly improve core behavioral outcomes, ...
In this valuable study, the authors develop new approaches to investigate mRNA imprinting, a phenomenon in which RNA-protein complexes form in the nucleus to influence the fate of transcripts in the ...
DELTA 3 enrolled 560 delgocitinib-treated completers from DELTA 1/2; 472 were week-52 completers after 16 weeks BID induction ...
India has slipped to the 6th-largest economy in the IMF's latest outlook. IndiaToday.in spoke to economists to understand why ...
Merck & Co. Inc. MRK and Eisai on Tuesday announced results from the Phase 3 LITESPARK-012 trial of combination drugs for ...
Propensity-matched analyses showed smokers had significantly higher risk across all studied ocular outcomes over 10 years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results